<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">19357408</PMID>
      <DateCompleted>
        <Year>2009</Year>
        <Month>04</Month>
        <Day>15</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>08</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1533-4406</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>360</Volume>
            <Issue>15</Issue>
            <PubDate>
              <Year>2009</Year>
              <Month>Apr</Month>
              <Day>09</Day>
            </PubDate>
          </JournalIssue>
          <Title>The New England journal of medicine</Title>
          <ISOAbbreviation>N Engl J Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Myocarditis.</ArticleTitle>
        <Pagination>
          <StartPage>1526</StartPage>
          <EndPage>1538</EndPage>
          <MedlinePgn>1526-38</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1056/NEJMra0800028</ELocationID>
        <Abstract>
          <AbstractText>Myocarditis may present with a wide range of symptoms, ranging from mild dyspnea or chest pain that resolves without specific therapy to cardiogenic shock and death. Dilated cardiomyopathy with chronic heart failure is the major long-term sequela of myocarditis. Most often, myocarditis results from common viral infections; less commonly, specific forms of myocarditis may result from other pathogens, toxic or hypersensitivity drug reactions, giant-cell myocarditis, or sarcoidosis. The prognosis and treatment of myocarditis vary according to the cause, and clinical and hemodynamic data usually provide guidance to decide when to refer a patient to a specialist for endomyocardial biopsy. The aim of this review is to provide a practical and current approach to the evaluation and treatment of suspected myocarditis.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Cooper</LastName>
            <ForeName>Leslie T</ForeName>
            <Initials>LT</Initials>
            <Suffix>Jr</Suffix>
            <AffiliationInfo>
              <Affiliation>Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN 55905, USA. cooper.leslie@mayo.edu</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 HL056267</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R56 HL056267</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>N Engl J Med</MedlineTA>
        <NlmUniqueID>0255562</NlmUniqueID>
        <ISSNLinking>0028-4793</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>N Engl J Med. 2009 Jul 23;361(4):422-3; author reply 423-4</RefSource>
          <PMID Version="1">19625725</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>N Engl J Med. 2009 Jul 23;361(4):423; author reply 423-4</RefSource>
          <PMID Version="1">19630148</PMID>
        </CommentsCorrections>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>N Engl J Med. 2009 Jul 23;361(4):423; author reply 423-4</RefSource>
          <PMID Version="1">19630149</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001145" MajorTopicYN="N">Arrhythmias, Cardiac</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002311" MajorTopicYN="N">Cardiomyopathy, Dilated</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004452" MajorTopicYN="N">Echocardiography</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004562" MajorTopicYN="N">Electrocardiography</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009205" MajorTopicYN="Y">Myocarditis</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
          <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009206" MajorTopicYN="N">Myocardium</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>No other potential conflict of interest relevant to this article was reported.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2009</Year>
          <Month>4</Month>
          <Day>10</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2009</Year>
          <Month>4</Month>
          <Day>10</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2009</Year>
          <Month>4</Month>
          <Day>16</Day>
          <Hour>9</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">19357408</ArticleId>
        <ArticleId IdType="mid">NIHMS940711</ArticleId>
        <ArticleId IdType="pmc">PMC5814110</ArticleId>
        <ArticleId IdType="doi">10.1056/NEJMra0800028</ArticleId>
        <ArticleId IdType="pii">360/15/1526</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Aretz HT, Billingham ME, Edwards WD, et al.  Myocarditis: a histopathologic definition and classification. Am J Cardiovasc Pathol. 1987;1:3–14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3455232</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chow LH, Radio SJ, Sears TD, McManus BM. Insensitivity of right ventricular endomyocardial biopsy in the diagnosis of myocarditis. J Am Coll Cardiol. 1989;14:915–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2794278</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baughman KL. Diagnosis of myocarditis: death of Dallas criteria. Circulation. 2006;113:593–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16449736</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herskowitz A, Ahmed-Ansari A, Neumann DA, et al.  Induction of major histocompatibility complex antigens within the myocardium of patients with active myocarditis: a nonhistologic marker of myocarditis. J Am Coll Cardiol. 1990;15:624–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2406319</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maisch B, Portig I, Ristic A, Hufnagel G, Pankuweit S. Definition of inflammatory cardiomyopathy (myocarditis): on the way to consensus: a status report. Herz. 2000;25:200–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10904839</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kindermann I, Kindermann M, Kandolf R, et al.  Predictors of outcome in patients with suspected myocarditis. Circulation. 2008;118:639–48. [Erratum, Circulation 2008;118(12):e493.]</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18645053</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mahrholdt H, Goedecke C, Wagner A, et al.  Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology. Circulation. 2004;109:1250–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14993139</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gutberlet M, Spors B, Thoma T, et al.  Suspected chronic myocarditis at cardiac MR: diagnostic accuracy and association with immunohistologically detected inflammation and viral persistence. Radiology. 2008;246:401–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18180335</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cooper LT, Baughman KL, Feldman AM, et al.  The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Circulation. 2007;116:2216–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17959655</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lieberman EB, Hutchins GM, Herskowitz A, Rose NR, Baughman KL. Clinicopathologic description of myocarditis. J Am Coll Cardiol. 1991;18:1617–26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1960305</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hare JM, Baughman KL. Fulminant and acute lymphocytic myocarditis: the prognostic value of clinicopathological classification. Eur Heart J. 2001;22:269–70.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11161940</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McCarthy RE, III, Boehmer JP, Hruban RH, et al.  Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N Engl J Med. 2000;342:690–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10706898</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McCully RB, Cooper LT, Schreiter S. Coronary artery spasm in lymphocytic myocarditis: a rare cause of acute myocardial infarction. Heart. 2005;91:202.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1768686</ArticleId>
            <ArticleId IdType="pubmed">15657232</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Magnani JW, Dec GW. Myocarditis: current trends in diagnosis and treatment. Circulation. 2006;113:876–90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16476862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hufnagel G, Pankuweit S, Richter A, Schönian U, Maisch B. The European Study of Epidemiology and Treatment of Cardiac Inflammatory Diseases (ESETCID): first epidemiological results. Herz. 2000;25:279–85.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10904853</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mason JW, O’Connell JB, Herskowitz A, et al.  A clinical trial of immunosuppressive therapy for myocarditis. N Engl J Med. 1995;333:269–75.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7596370</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caforio A, Calabrese F, Angelini A, et al.  A prospective study of biopsy-proven myocarditis: prognostic relevance of clinical and aetiopathogenetic features at diagnosis. Eur Heart J. 2007;28:1326–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17493945</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Magnani JW, Danik HJ, Dec GW, Jr, DiSalvo TG. Survival in biopsy-proven myocarditis: a long-term retrospective analysis of the histopathologic, clinical, and hemodynamic predictors. Am Heart J. 2006;151:463–70.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16442915</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schwartz J, Sartini D, Huber S. Myocarditis susceptibility in female mice depends upon ovarian cycle phase at infection. Virology. 2004;330:16–23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15527830</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amabile NF, Fraisse A, Bouvenot A, Chetaille P, Ovaert C. Outcome of acute fulminant myocarditis in children. Heart. 2006;92:1269–73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1861180</ArticleId>
            <ArticleId IdType="pubmed">16449512</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yazaki Y, Isobe M, Hiramitsu S, et al.  Comparison of clinical features and prognosis of cardiac sarcoidosis and idiopathic dilated cardiomyopathy. Am J Cardiol. 1998;82:537–40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9723651</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pallansch MA. Coxsackievirus B epidemiology and public health concerns. Curr Top Microbiol Immunol. 1997;223:13–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9294923</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maron BJ, Doerer JJ, Haas TS, Tierney DM, Mueller FO. Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980-2006. Circulation. 2009;119:1085–92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19221222</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nugent AW, Daubeney PEF, Chondros P, et al.  The epidemiology of childhood cardiomyopathy in Australia. N Engl J Med. 2003;348:1639–46.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12711738</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Towbin JA, Lowe AM, Colan SD, et al.  Incidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA. 2006;296:1867–76.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17047217</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kühl U, Pauschinger M, Noutsias M, et al.  High prevalence of viral genomes and multiple viral infections in the myocardium of adults with “idiopathic” left ventricular dysfunction. Circulation. 2005;111:887–93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15699250</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsumori A, Shimada T, Chapman NM, Tracy SM, Mason JW. Myocarditis and heart failure associated with hepatitis C virus infection. J Card Fail. 2006;12:293–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16679263</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsumori A. Hepatitis C virus infection and cardiomyopathies. Circ Res. 2005;96:144–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15692092</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jahangir A, Kolbert C, Edwards W, Mitchell P, Dumler JS, Persing DH. Fatal pancarditis associated with human granulocytic Ehrlichiosis in a 44-year-old man. Clin Infect Dis. 1998;27:1424–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9868655</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McAlister HF, Klementowicz PT, Andrews C, Fisher JD, Feld M, Furman S. Lyme carditis: an important cause of reversible heart block. Ann Intern Med. 1989;110:339–45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2644885</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rassi A, Jr, Rassi A, Little WC, et al.  Development and validation of a risk score for predicting death in Chagas’ heart disease. N Engl J Med. 2006;355:799–808.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16928995</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen F, Shannon K, Ding S, et al.  HIV type 1 glycoprotein 120 inhibits cardiac myocyte contraction. AIDS Res Hum Retroviruses. 2002;18:777–84.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12167269</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taliercio CP, Olney BA, Lie JT. Myocarditis related to drug hypersensitivity. Mayo Clin Proc. 1985;60:463–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">4010343</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Corssmit EP, Trip MD, Durrer JD. Löffler’s endomyocarditis in the idiopathic hypereosinophilic syndrome. Cardiology. 1999;91:272–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10545685</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spodick DH. Eosinophilic myocarditis. Mayo Clin Proc. 1997;72:996.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9379706</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Corradi D, Vaglio A, Maestri R, et al.  Eosinophilic myocarditis in a patient with idiopathic hypereosinophilic syndrome: insights into mechanisms of myocardial cell death. Hum Pathol. 2004;35:1160–3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15343520</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barton M, Finkelstein Y, Opavsky M, et al.  Eosinophilic myocarditis temporally associated with conjugate meningococcal C and hepatitis B vaccines in children. Pediatr Infect Dis J. 2008;27:831–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18664932</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arness MK, Eckart RE, Love SS, et al.  Myopericarditis following smallpox vaccination. Am J Epidemiol. 2004;160:642–51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15383408</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cooper LT, Zehr KJ. Biventricular assist device placement and immunosuppression as therapy for necrotizing eosinophilic myocarditis. Nat Clin Pract Cardiovasc Med. 2005;2:544–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16186853</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cooper LT, Jr, Berry GJ, Shabetai R. Idiopathic giant-cell myocarditis — natural history and treatment. N Engl J Med. 1997;336:1860–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9197214</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kilgallen CM, Jackson E, Bankoff M, Salomon RN, Surks HK. A case of giant cell myocarditis and malignant thymoma: a postmortem diagnosis by needle biopsy. Clin Cardiol. 1998;21:48–51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6655838</ArticleId>
            <ArticleId IdType="pubmed">9474466</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Daniels P, Tazelaar H, Edwards W, Cooper L. Giant cell myocarditis as a manifestation of drug hypersensitivity. Cardiovasc Pathol. 2000;9:287–91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11064276</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rahman JE, Helou EF, Gelzer-Bell R, et al.  Noninvasive diagnosis of biopsyproven cardiac amyloidosis. J Am Coll Cardiol. 2004;43:410–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15013123</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frustaci A, Verardo R, Caldarulo M, Acconcia MC, Russo MA, Chimenti C. Myocarditis in hypertrophic cardiomyopathy patients presenting acute clinical deterioration. Eur Heart J. 2007;28:733–40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17309901</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chimenti C, Pieroni M, Maseri A, Frustaci A. Histologic findings in patients with clinical and instrumental diagnosis of sporadic arrhythmogenic right ventricular dysplasia. J Am Coll Cardiol. 2004;43:2305–13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15193698</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Basso C, Ronco F, Marcus F, et al.  Quantitative assessment of endomyocardial biopsy in arrhythmogenic right ventricular cardiomyopathy/dysplasia: an in vitro validation of diagnostic criteria. Eur Heart J. 2008;29:2760–71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18819962</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bowles NE, Ni J, Marcus F, Towbin JA. The detection of cardiotropic viruses in the myocardium of patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol. 2002;39:892–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11869858</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andréoletti L, Ventéo L, Douche-Aourik F, et al.  Active Coxsackieviral B infection is associated with disruption of dystrophin in endomyocardial tissue of patients who died suddenly of acute myocardial infarction. J Am Coll Cardiol. 2007;50:2207–14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18061067</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tam PE. Coxsackievirus myocarditis: interplay between virus and host in the pathogenesis of heart disease. Viral Immunol. 2006;19:133–46.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16817756</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bergelson JM, Cunningham JA, Drouguett G, et al.  Isolation of a common receptor for Coxsackie B virus and adenoviruses types 2 and 5. Science. 1997;275:1320–3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9036860</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coyne CB, Bergelson JM. Virus-induced Abl and Fyn kinase signals permit coxsackievirus entry through epithelial tight junctions. Cell. 2006;124:119–31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16413486</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martino TA, Petric M, Brown M, et al.  Cardiovirulent coxsackieviruses and the decay-accelerating factor (CD55) receptor. Virology. 1998;244:302–14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9601501</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tracy S, Höfling K, Pirruccello S, Lane PH, Reyna SM, Gauntt CJ. Group B coxsackievirus myocarditis and pancreatitis: connection between viral virulence phenotypes in mice. J Med Virol. 2000;62:70–81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10935991</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beck MA, Shi Q, Morris VC, Levander OA. Rapid genomic evolution of a nonvirulent coxsackievirus B3 in selenium-deficient mice results in selection of identical virulent isolates. Nat Med. 1995;1:433–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7585090</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ilbäck NG, Wesslén L, Fohlman J, Friman G. Effects of methyl mercury on cytokines, inflammation and virus clearance in a common infection (coxsackie B3 myocarditis) Toxicol Lett. 1996;89:19–28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8952707</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cooper LT, Rader V, Ralston NV. The roles of selenium and mercury in the pathogenesis of viral cardiomyopathy. Congest Heart Fail. 2007;13:193–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17673870</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gifford R, Dalldorf G. Morbid anatomy of experimental Coxsackie virus infection. Am J Pathol. 1951;27:1047–63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1937323</ArticleId>
            <ArticleId IdType="pubmed">14885400</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gauntt CJ, Pallansch MA. Coxsackievirus B3 clinical isolates and murine myocarditis. Virus Res. 1996;41:89–99. [Erratum, Virus Res 1996;45:69.]</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8725105</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matzinger P. The danger model: a renewed sense of self. Science. 2002;296:301–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11951032</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fuse K, Chan G, Liu Y, et al.  Myeloid differentiation factor-88 plays a crucial role in the pathogenesis of Coxsackievirus B3-induced myocarditis and influences type I interferon production. Circulation. 2005;112:2276–85.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16216974</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fairweather D, Frisancho-Kiss S, Rose NR. Viruses as adjuvants for autoimmunity: evidence from Coxsackievirus-induced myocarditis. Rev Med Virol. 2005;15:17–27.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15386590</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frisancho-Kiss S, Davis SE, Nyland JF, et al.  Cutting edge: cross-regulation by TLR4 and T cell Ig mucin-3 determines sex differences in inflammatory heart disease. J Immunol. 2007;178:6710–4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17513715</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fairweather D, Frisancho-Kiss S, Gatewood S, et al.  Mast cells and innate cytokines are associated with susceptibility to autoimmune heart disease following coxsackievirus B3 infection. Autoimmunity. 2004;37:131–45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15293883</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eriksson U, Ricci R, Hunziker L, et al.  Dendritic cell-induced autoimmune heart failure requires cooperation between adaptive and innate immunity. Nat Med. 2003;9:1484–90. [Erratum, Nat Med 2004;10: 105.]</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14625544</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kodama M, Hanawa H, Saeki M, et al.  Rat dilated cardiomyopathy after autoimmune giant cell myocarditis. Circ Res. 1994;75:278–84.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8033341</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zehn D, Bevan MJ. T cells with a low avidity for a tissue-restricted antigen routinely evade central and peripheral tolerance and cause autoimmunity. Immunity. 2006;25:261–70.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2774714</ArticleId>
            <ArticleId IdType="pubmed">16879996</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huber SA, Pfaeffle B. Differential Th1 and Th2 cell responses in male and female BALB/c mice infected with coxsackievirus group B type 3. J Virol. 1994;68:5126–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC236456</ArticleId>
            <ArticleId IdType="pubmed">8035512</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilson NJ, Boniface K, Chan JR, et al.  Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol. 2007;8:950–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17676044</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rangachari M, Mauermann N, Marty RR, et al.  T-bet negatively regulates autoimmune myocarditis by suppressing local production of interleukin 17. J Exp Med. 2006;203:2009–19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2118365</ArticleId>
            <ArticleId IdType="pubmed">16880257</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Opavsky MA, Penninger J, Aitken K, et al.  Susceptibility to myocarditis is dependent on the response of alphabeta T lymphocytes to coxsackieviral infection. Circ Res. 1999;85:551–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10488058</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Perens G, Levi DS, Alejos JC, Wetzel GT. Muronomab-CD3 for pediatric acute myocarditis. Pediatr Cardiol. 2007;28:21–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17165111</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell. 2000;101:455–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10850488</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ono M, Shimizu J, Miyachi Y, Sakaguchi S. Control of autoimmune myocarditis and multiorgan inflammation by glucocorticoid-induced TNF receptor family-related protein(high), Foxp3-expressing CD25+ and CD25− regulatory T cells. J Immunol. 2006;176:4748–56.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16585568</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huber SA, Feldman AM, Sartini D. Coxsackievirus B3 induces T regulatory cells, which inhibit cardiomyopathy in tumor necrosis factor-alpha transgenic mice. Circ Res. 2006;99:1109–16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17038643</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caforio AL, Mahon NJ, Tona F, Mc-Kenna WJ. Circulating cardiac autoantibodies in dilated cardiomyopathy and myocarditis: pathogenetic and clinical significance. Eur J Heart Fail. 2002;4:411–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12167378</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schulze K, Becker BF, Schauer R, Schultheiss HP. Antibodies to ADP-ATP carrier — an autoantigen in myocarditis and dilated cardiomyopathy — impair cardiac function. Circulation. 1990;81:959–69.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2155073</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Y, Heuser JS, Cunningham LC, Kosanke SD, Cunningham MW. Mimicry and antibody-mediated cell signaling in autoimmune myocarditis. J Immunol. 2006;177:8234–40.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17114501</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Galvin JE, Hemric ME, Ward K, Cunningham MW. Cytotoxic mAb from rheumatic carditis recognizes heart valves and laminin. J Clin Invest. 2000;106:217–24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC314302</ArticleId>
            <ArticleId IdType="pubmed">10903337</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Antone SM, Adderson EE, Mertens NM, Cunningham MW. Molecular analysis of V gene sequences encoding cytotoxic anti-streptococcal/anti-myosin monoclonal antibody 36.2.2 that recognizes the heart cell surface protein laminin. J Immunol. 1997;159:5422–30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9548482</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huber SA, Budd RC, Rossner K, Newell MK. Apoptosis in coxsackievirus B3-induced myocarditis and dilated cardiomyopathy. Ann N Y Acad Sci. 1999;887:181–90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10668474</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Badorff C, Lee GH, Lamphear BJ, et al.  Enteroviral protease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy. Nat Med. 1999;5:320–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10086389</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Badorff C, Knowlton KU. Dystrophin disruption in enterovirus-induced myocarditis and dilated cardiomyopathy: from bench to bedside. Med Microbiol Immunol. 2004;193:121–6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12920582</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim KS, Tracy S, Tapprich W, et al.  5′-Terminal deletions occur in coxsackievirus B3 during replication in murine hearts and cardiac myocyte cultures and correlate with encapsidation of negativestrand viral RNA. J Virol. 2005;79:7024–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1112132</ArticleId>
            <ArticleId IdType="pubmed">15890942</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Y, Bourlet T, Andreoletti L, et al.  Enteroviral capsid protein VP1 is present in myocardial tissues from some patients with myocarditis or dilated cardiomyopathy. Circulation. 2000;101:231–4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10645916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith SC, Ladenson JH, Mason JW, Jaffe AS. Elevations of cardiac troponin I associated with myocarditis: experimental and clinical correlates. Circulation. 1997;95:163–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8994432</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lauer B, Niederau C, Kühl U, et al.  Cardiac troponin T in patients with clinically suspected myocarditis. J Am Coll Cardiol. 1997;30:1354–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9350939</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sheppard R, Bedi M, Kubota T, et al.  Myocardial expression of fas and recovery of left ventricular function in patients with recent-onset cardiomyopathy. J Am Coll Cardiol. 2005;46:1036–42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16168288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nishii M, Inomata T, Takehana H, et al.  Serum levels of interleukin-10 on admission as a prognostic predictor of human fulminant myocarditis. J Am Coll Cardiol. 2004;44:1292–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15364334</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morgera T, Di Lenarda A, Dreas L, et al.  Electrocardiography of myocarditis revisited: clinical and prognostic significance of electrocardiographic changes. Am Heart J. 1992;124:455–67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1636589</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakashima H, Katayama T, Ishizaki M, Takeno M, Honda Y, Yano K. Q wave and non-Q wave myocarditis with special reference to clinical significance. Jpn Heart J. 1998;39:763–74.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10089938</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Angelini A, Calzolari V, Calabrese F, et al.  Myocarditis mimicking acute myocardial infarction: role of endomyocardial biopsy in the differential diagnosis. Heart. 2000;84:245–50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1760950</ArticleId>
            <ArticleId IdType="pubmed">10956283</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mendes LA, Picard MH, Dec GW, Hartz VL, Palacios IF, Davidoff R. Ventricular remodeling in active myocarditis: Myocarditis Treatment Trial. Am Heart J. 1999;138:303–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10426843</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Felker GM, Boehmer JP, Hruban RH, et al.  Echocardiographic findings in fulminant and acute myocarditis. J Am Coll Cardiol. 2000;36:227–32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10898439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mendes LA, Dec GW, Picard MH, Palacios IF, Newell J, Davidoff R. Right ventricular dysfunction: an independent predictor of adverse outcome in patients with myocarditis. Am Heart J. 1994;128:301–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8037097</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Laissy JP, Messin B, Varenne O, et al.  MRI of acute myocarditis: a comprehensive approach based on various imaging sequences. Chest. 2002;122:1638–48.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12426265</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Friedrich MG, Strohm O, Schulz-Menger J, Marciniak H, Luft FC, Dietz R. Contrast media-enhanced magnetic resonance imaging visualizes myocardial changes in the course of viral myocarditis. Circulation. 1998;97:1802–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9603535</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abdel-Aty H, Boyé P, Zagrosek A, et al.  Diagnostic performance of cardiovascular magnetic resonance in patients with suspected acute myocarditis: comparison of different approaches. J Am Coll Cardiol. 2005;45:1815–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15936612</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hunt S. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure) J Am Coll Cardiol. 2005;46(6):e1–e82. [Erratum, J Am Coll Cardiol 2006;47:1503-5.]</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16168273</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adams K, Lindenfeld J, Arnold J, Heart Failure Society of America  Executive summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline. J Card Fail. 2006;12:10–38.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16500578</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dickstein K, Cohen-Solal A, Filippatos G, et al.  ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) Eur J Heart Fail. 2008;10:933–89.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18826876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Farrar DJ, Holman WR, McBride LR, et al.  Long-term follow-up of Thoratec ventricular assist device bridge-to-recovery patients successfully removed from support after recovery of ventricular function. J Heart Lung Transplant. 2002;21:516–21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11983540</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen YS, Yu HY. Choice of mechanical support for fulminant myocarditis: ECMO vs. VAD? Eur J Cardiothorac Surg. 2005;27:931–2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15848345</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Topkara VK, Dang NC, Barili F, et al.  Ventricular assist device use for the treatment of acute viral myocarditis. J Thorac Cardiovasc Surg. 2006;131:1190–1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16678619</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moloney ED, Egan JJ, Kelly P, Wood AE, Cooper LT., Jr Transplantation for myocarditis: a controversy revisited. J Heart Lung Transplant. 2005;24:1103–10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16102447</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cabinian AE, Kiel RJ, Smith F, Ho KL, Khatib R, Reyes MP. Modification of exercise-aggravated coxsackievirus B3 murine myocarditis by T lymphocyte suppression in an inbred model. J Lab Clin Med. 1990;115:454–62.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2157783</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maron BJ, Ackerman MJ, Nishimura RA, Pyeritz RE, Towbin JA, Udelson JE. Task Force 4: HCM and other cardiomyopathies, mitral valve prolapse, myocarditis, and Marfan syndrome. J Am Coll Cardiol. 2005;45:1340–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15837284</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saegusa S, Fei Y, Takahashi T, et al.  Oral administration of candesartan improves the survival of mice with viral myocarditis through modification of cardiac adiponectin expression. Cardiovasc Drugs Ther. 2007;21:155–60.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17484035</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tominaga M, Matsumori A, Okada I, Yamada T, Kawai C. Beta-blocker treatment of dilated cardiomyopathy: beneficial effect of carteolol in mice. Circulation. 1991;83:2021–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1674900</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khatib R, Reyes MP, Smith F, Khatib G, Rezkalla S. Enhancement of coxsackievirus B4 virulence by indomethacin. J Lab Clin Med. 1990;116:116–20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1695914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Costanzo-Nordin MR, Reap EA, O’Connell JB, Robinson JA, Scanlon PJ. A nonsteroid anti-inflammatory drug exacerbates Coxsackie B3 murine myocarditis. J Am Coll Cardiol. 1985;6:1078–82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2995470</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rezkalla S, Khatib R, Khatib G, et al.  Effect of indomethacin in the late phase of coxsackievirus myocarditis in a murine model. J Lab Clin Med. 1988;112:118–21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2839587</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zipes D, Camm A, Borggrefe M, et al.  ACC/AHA/ESC 2006 guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114(10):e385–e484.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16935995</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuhl U, Pauschinger M, Seeberg B, et al.  Viral persistence in the myocardium is associated with progressive cardiac dysfunction. Circulation. 2005;112:1965–70.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16172268</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsumori A, Crumpacker CS, Abelmann WH. Prevention of viral myocarditis with recombinant human leukocyte interferon alpha A/D in a murine model. J Am Coll Cardiol. 1987;9:1320–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3034992</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okada I, Matsumori A, Matoba Y, Tominaga M, Yamada T, Kawai C. Combination treatment with ribavirin and interferon for coxsackievirus B3 replication. J Lab Clin Med. 1992;120:569–73.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1328433</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ray CG, Icenogle TB, Minnich LL, Copeland JG, Grogan TM. The use of intravenous ribavirin to treat influenza virus-associated acute myocarditis. J Infect Dis. 1989;159:829–36. [Erratum, J Infect Dis 1989;160:564.]</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2775346</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kühl U, Pauschinger M, Schwimmbeck PL, et al.  Interferon-beta treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation. 2003;107:2793–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12771005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mahrholdt H, Wagner A, Deluigi CC, et al.  Presentation, patterns of myocardial damage, and clinical course of viral myocarditis. Circulation. 2006;114:1581–90.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17015795</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McNamara DM, Holubkov R, Starling RC, et al.  Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation. 2001;103:2254–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11342473</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drucker NA, Colan SD, Lewis AB, et al.  Gamma-globulin treatment of acute myocarditis in the pediatric population. Circulation. 1994;89:252–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8281654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parrillo JE, Cunnion RE, Epstein SE, et al.  A prospective, randomized, controlled trial of prednisone for dilated cardiomyopathy. N Engl J Med. 1989;321:1061–8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2677721</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stanton C, Mookadam F, Cha S, et al.  Greater symptom duration predicts response to immunomodulatory therapy in dilated cardiomyopathy. Int J Cardiol. 2008;128:38–41.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17707091</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wojnicz R, Nowalany-Kozielska E, Wojciechowska C, et al.  Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: two-year follow-up results. Circulation. 2001;104:39–45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11435335</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Torre-Amione G, Anker SD, Bourge RC, et al.  Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial. Lancet. 2008;371:228–36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18207018</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Staudt A, Hummel A, Ruppert J, et al.  Immunoadsorption in dilated cardiomyopathy: 6-month results from a randomized study. Am Heart J. 2006;152(4):712e1–712.e6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16996843</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oberg AL, Mahoney DW, Eckel-Passow JE, et al.  Statistical analysis of relative labeled mass spectrometry data from complex samples using ANOVA. J Proteome Res. 2008;7:225–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2528956</ArticleId>
            <ArticleId IdType="pubmed">18173221</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
